Urology

Reports of high-impact urology studies by medical professionals

Daily aspirin may not improve overall prostate cancer mortality

1. Aspirin use pre- or post-diagnosis of prostate cancer was not significant associated with a decrease in prostate-cancer specific survival.2. Post-diagnosis daily aspirin use...

Preoperative MRI improves surgical outcomes in robotic prostatectomy

1. Among prostate cancer patients treated with robot-assisted radical prostatectomy, the use of preoperative prostate magnetic resonance (MR) imaging significantly reduced the risk of...

Urinary HPV testing accurate for cervical HPV detection

1. Urinary HPV testing showed a high sensitivity and specificity for detecting cervical HPV, and an especially high specificity for strains 16 and 18....

ACP recommends non-pharmacologic treatment of urinary incontinence in women

1. According to a new practice guideline from the American College of Physicians, non-pharmacological therapies for urinary incontinence (UI) in women, such as pelvic...

Prostate cancer screening shows reduction in mortality after 13 year follow-up [ERSPC trial]

1. Prostate cancer screening showed a continued reduction in prostate cancer incidence and mortality after a longer follow-up of 13 years compared to previous...

Strict blood pressure control in kidney disease linked to worse outcomes

1. Among patients with chronic kidney disease, a goal systolic blood pressure between 120-139 mmHg was associated with a lower mortality rate than a...

Shorter surveillance follow-up for stage I seminoma may be sufficient

1. A large, retrospective, population-based study of stage I seminoma patients followed by active surveillance post-orchiectomy demonstrated that the majority of relapses occurred within...

Increased risk of aggressive prostate cancer following vasectomy

1. Vasectomy was associated with a small increased risk of aggressive prostate cancer on extended long-term follow-up.Evidence Rating Level: 2 (Good)Study Rundown: The association...

Novel aromatase inhibitor, ODM-201, may be safe and effective for prostate cancer

1. In a phase I trial, ODM-201 was well tolerated up to 1800mg per day in prostate cancer patients, without reaching the maximum tolerated...

Obesity linked with prostate cancer progression

1. In men with low-risk prostate cancer undergoing active surveillance, obesity (BMI>30) was significantly associated with pathologic and therapeutic progression after the first confirmatory...
licensing as small

All-time hits